• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

痤疮:环孢素A治疗的一种潜在副作用。

Acne: a potential side effect of cyclosporine A therapy.

作者信息

el-Shahawy M A, Gadallah M F, Massry S G

机构信息

Department of Medicine, USC School of Medicine, Los Angeles 90033 USA.

出版信息

Nephron. 1996;72(4):679-82. doi: 10.1159/000188960.

DOI:10.1159/000188960
PMID:8730442
Abstract

A renal transplant recipient who developed severe acne 6 months after transplantation is described. Maintenance immunosuppression consisted of cyclosporine A (CsA), azathioprine and prednisone. Tapering the prednisone dose to as low as 5 mg/day, in addition to topical tetracycline, Retin-A cream, and systemic antimicrobial therapy failed to control the progression of the skin lesions. Despite therapy with isotretinoin (Accutane), the lesions continued to progress with nodulocystic transformation (acne conglobata) and isotretinoin was discontinued after 4 months. However, the condition continued to worsen with the development of a systemic illness with daily fever, diaphoresis, and depression. High fever (103 degrees F) with shaking chills prompted hospitalization. Withdrawal of CsA resulted in rapid and continuous improvement of the skin lesions. After 12 months of follow-up, the lesions significantly resolved except for residual areas of scarring. No episodes of acute allograft rejection occurred. In conclusion, we suggest that CsA therapy may be associated with the development of acne. Nodulocystic transformation (acne conglobata) may occur despite the use of isotretinoin. Finally, withdrawal of CsA may lead to resolution of the skin disease and should, therefore, be considered as a therapeutic option for severe and treatment-resistant cases.

摘要

本文描述了一位肾移植受者,其在移植后6个月出现了严重痤疮。维持性免疫抑制治疗包括环孢素A(CsA)、硫唑嘌呤和泼尼松。除了外用四环素、维甲酸乳膏和全身抗菌治疗外,将泼尼松剂量减至低至5毫克/天仍未能控制皮肤病变的进展。尽管使用异维A酸(泰尔丝)治疗,病变仍继续进展并出现结节囊肿性转变(聚合性痤疮),4个月后停用异维A酸。然而,病情继续恶化,出现了每日发热、多汗和抑郁的全身性疾病。高热(华氏103度)伴寒战促使患者住院。停用CsA后,皮肤病变迅速且持续改善。经过12个月的随访,除了残留的瘢痕区域外,病变明显消退。未发生急性移植肾排斥反应。总之,我们认为CsA治疗可能与痤疮的发生有关。尽管使用了异维A酸,仍可能发生结节囊肿性转变(聚合性痤疮)。最后,停用CsA可能导致皮肤病消退,因此,对于严重且难治性病例应考虑将其作为一种治疗选择。

相似文献

1
Acne: a potential side effect of cyclosporine A therapy.痤疮:环孢素A治疗的一种潜在副作用。
Nephron. 1996;72(4):679-82. doi: 10.1159/000188960.
2
Cyclosporine-induced infantile nodulocystic acne.环孢素诱发的婴儿结节囊肿性痤疮。
Arch Dermatol. 2009 Jul;145(7):797-9. doi: 10.1001/archdermatol.2009.98.
3
Acne conglobata: treatment with isotretinoin, colchicine, and cyclosporin as compared with surgical intervention.聚合性痤疮:异维A酸、秋水仙碱和环孢素治疗与手术干预的比较
Clin Exp Dermatol. 1996 Nov;21(6):462-3. doi: 10.1111/j.1365-2230.1996.tb00160.x.
4
Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.异维A酸治疗后痤疮复发:405例患者的回顾性研究
J Drugs Dermatol. 2008 Oct;7(10):963-6.
5
Hemodialysis-related nodulocystic acne treated with isotretinoin.异维A酸治疗血液透析相关的结节囊肿性痤疮。
Nephron. 1999 Feb;81(2):146-50. doi: 10.1159/000045270.
6
Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne.壬二酸乳膏联合口服米诺环素与口服异维A酸治疗重度痤疮的比较
Eur J Dermatol. 2001 Nov-Dec;11(6):538-44.
7
Medium dose isotretinoin for the treatment of acne.中等剂量异维A酸治疗痤疮
J Eur Acad Dermatol Venereol. 1998 Sep;11(2):117-21.
8
[Aggravation of acne by isotretinoin. 6 cases, predictive factors].[异维A酸加重痤疮。6例及预测因素]
Ann Dermatol Venereol. 1998 Aug;125(8):496-9.
9
Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone.异维A酸治疗期间出现暴发性痤疮和结节性红斑,对氨苯砜治疗有效。
Clin Exp Dermatol. 1997 Jan;22(1):26-7. doi: 10.1046/j.1365-2230.1997.1830600.x.
10
Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients.100例寻常痤疮患者中与异维A酸治疗相关的抑郁发生率。
Psychol Rep. 2006 Dec;99(3):897-906. doi: 10.2466/PR0.99.3.897-906.